Boehringer Ingelheim achieves growth in first half of 2012

Boehringer Ingelheim has published its financial results for the first half of 2012, during which it experienced strong year-on-year growth.

The company's currency-adjusted sales total for the six months came to 7.1 billion euros (5.58 billion pounds), up by 6.8 percent annually, thanks in large part to the momentum of products such as Spiriva, Combivent, Pradaxa and Trajenta.

Emerging markets and the US were highlighted as delivering particularly strong performances, but the company warned that depressed macroeconomic conditions will create challenges during the second half of the year.

As such, Boehringer Ingelheim will make efforts to progress the development of its new product pipeline, which will help it achieve single-digit sales growth for 2012 as a whole.

Professor Andreas Barner, chairman of the board of managing directors at Boehringer Ingelheim, said: "We will provide new medications, especially for treatment in the areas of diabetes, oncology, hepatitis C, idiopathic pulmonary fibrosis and other respiratory tract diseases."

Earlier this month, the company announced a new collaboration with Servier regarding the manufacturing of a new antibody called gevokizumab.